Browse our interactive material, read recent ALS publications and news articles, or find information on our upcoming events.
The bill, which now needs only Obama's signature to become a law, will make critical technology available to patients with ALS and other neurological disorders through Medicare and Medicaid. That includes innovative speech-generating devices like the one Gleason uses to type words through eye movements.
The ALS Association and the ALS Finding a Cure Foundation are pleased to announce $3 million in funding for two new Phase II clinical studies through the ALS Accelerated Therapeutics (ALS ACT) initiative.
07/13/2015: Robert G. Miller awarded $1.5 million grant to help fund Neuraltus' Phase 2 clinical study
The Phase 2 study is intended to help confirm the potential clinical benefits seen in the previous study of NP001, the results from which were published in the April 2015 issue of Neurology: Neuroimmunology & Neuroinflammation, an official journal of the American Academy of Neurology.
05/12/2015: MGH ALS Symposium Video
Hear from the MGH Neurology Department researchers and clinic staff dedicated to finding treatments and cures for ALS.
08/15/2014: Dousing for donations
The MGH ALS Multidisciplinary Clinic and the Northeast ALS Consortium participated in the Ice Bucket Challenge on Aug. 8.
The Northeast ALS Consortium (NEALS) website is devoted to supporting clinical research of Amyotrophic Lateral Sclerosis (ALS) and other motor neuron disease (MND).
01/30/2014: Calling all Veterans
Military veterans who are diagnosed with ALS are eligible for service-connected benefits.
01/30/2014: ALS Clinical Trials Liaison Available to Help Connect PALS With Clinical Research Information
NEALS and ALSA partner to offer clinical trial liaison service to help people with ALS navigate the world of clinical research.
Formal statement on the forthcoming US Brainstorm trial
12/01/2013: Strides in Understanding and Treating ALS
The Northeast ALS Consortium, co-founded by Massachusetts General Hospital researcher Merit Cudkowicz, MD, has spurred basic and translational research that has led to investigational therapies and improved patient outcomes.
12/22/2014: NeuroImage: Clinical
Increased in vivo glial activation in patients with amyotrophic lateral sclerosis: Assessed with [11
Evidence from human post mortem, in vivo and animal model studies implicates the neuroimmune system and activated microglia in the pathology of amyotrophic lateral sclerosis.
09/23/2013: The Lancet: Neurology
Dexpramipexole vs placebo for patients with ALS (EMPOWER): a randomised, double-blind, phase 3 trial
In a phase III trial, dexpramipexole was generally well tolerated but did not differ from placebo on any pre-specified efficacy endpoint measurement. The trial can inform the design of future clinical research strategies in amyotrophic lateral sclerosis.
05/16/2012: Amyotrophic Lateral Sclerosis
Safety, tolerability and pharmacodynamics of a skeletal muscle activator in amyotrophic lateral scle
Published Phase II results demonstrated that single oral doses of 250 mg and 500 mg of CK-2017357 appeared safe and well-tolerated in patients with ALS.
03/13/2012: Stem Cells
Lumbar Intraspinal Injection of Neural Stem Cells in Patients with ALS: Results of a Phase I Trial i
The results of an ongoing Phase I trial of intraspinal injections of fetal-derived neural stems cells in patients with ALS.
11/20/2011: Nature Medicine
The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis
Phase II, two-part trial examining safety and tolerability of dexpramipexole in patients with ALS.
05/23/2010: Therapy Times
Tuesdays With an SLP
Paige Nalipinski, senior speech language pathologist and project coordinator at MGH, writes about ALS care guidelines and her experience working with patients at the MGH ALS Multidisciplinary Clinic.
05/01/2010: Lancet Neurology
Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral scl
Double-blind, placebo-controlled trial with a time-to-event design assessing the safety and efficacy of lithium in combination with riluzole in patients with ALS.
07/01/2008: Muscle & Nerve
Arimoclomol at dosages up to 300 mg/day is well tolerated and safe in amyotrophic lateral sclerosis.
Safety, tolerability, and pharmacokinetics of arimoclomol in ALS were assessed.
07/01/2006: Annals of Neurology
Trial of celecoxib in amyotrophic lateral sclerosis
A double-blind, placebo-controlled, clinical trial to determine if celecoxib is safe and effective in ALS.
Tolerance of high-dose (3,000 mg/day) coenzyme Q10 in ALS
An open-label dose-escalation trial was performed to assess the safety and tolerability of high doses of coenzyme Q10 (CoQ10) in ALS.
A clinical trial of creatine in ALS
A randomized double-blind, placebo controlled trial on 104 patients with ALS from 14 sites to evaluate the efficacy of creatine supplementation in ALS.
A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis
A double-blind, placebo-controlled, multicenter randomized clinical trial to determine if long-term topiramate therapy is safe and slows disease progression in patients with ALS.
05/09/2015: MGH ALS Symposium
Please join us for an open exchange of data and ideas to help us succeed in our mission to find cures for ALS and provide excellence in care for people and their families with ALS.
01/01/2012: Continuing Medical Education in Neurology
The Neurology Service at Mass General offers Continuing Medical Education through Harvard Medical School.
Nicole from Boston, shares her story about her battle with ALS and her strong desire to help others with the disease in the future. Mass General's ALS Multidisciplinary Clinic provides the latest treatments and research opportunities for people with Amyotrophic Lateral Sclerosis.
Congratulations to Dr. Merit Cudkowicz, MGH Neurology Department Chairperson and Director, MGH ALS Clinic, for receiving the MDA LOU GEHRIG HUMANITARIAN AWARD. This award is given to a researcher, physician, or clinician who supports MDA/ALS research initiatives and clinical services and continues to fight the battle against ALS. View her acceptance speech where she discusses reasons for hope in the future of ALS treatments.